/DYN
DYN Stock - Dyne Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$19.85+7.01%
+$1.30 (+7.01%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.83
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.68
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+73.4%upside
Target: $34.42
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for DYN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$19.65 – $20.05
TARGET (TP)$34.42
STOP LOSS$18.26
RISK/REWARD1:9.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.30
52W High$26.22
52W Low$6.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-2,243,000 | $-2,461,000 | N/A | N/A | $-700,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-343,886,000 | $-242,162,000 | $-170,962,000 | $-150,025,000 | $-58,647,000 |
| Net Income | $-317,418,000 | $-235,937,000 | $-168,099,000 | $-149,291,000 | $-58,737,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-3.37 | $-3.95 | $-3.23 | $-2.93 | $-1.24 |
Company Overview
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Visit WebsiteRating Distribution
Strong Buy
2
12%
Buy / Outperform
14
82%
Hold / Neutral
1
6%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
16 Bullish1 Neutral/Bearish
Price Targets
$36
Average Target
↑ 79.0% Upside
Now
$13
Low
$36
Average
$50
High
Based on 19 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | Oppenheimer | Upgrade | Outperform | $40 |
| October 10th 2025 | Oppenheimer | Downgrade | Perform | - |
| August 25th 2025 | Raymond James | Upgrade | Strong Buy | $35 |
| June 24th 2025 | Bernstein | Initiation | Market Perform | $13 |
| June 11th 2025 | Raymond James | Resumed | Outperform | $37 |
| June 2nd 2025 | Oppenheimer | Resumed | Outperform | $34 |
| May 29th 2025 | Evercore ISI | Initiation | Outperform | $46 |
| March 12th 2025 | BMO Capital Markets | Initiation | Outperform | $50 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $50 |
| December 13th 2024 | Robert W. Baird | Initiation | Outperform | $46 |
| November 26th 2024 | RBC Capital Mkts | Initiation | Outperform | $45 |
| October 24th 2024 | JP Morgan | Downgrade | Neutral | $35← $43 |
| May 21st 2024 | Chardan Capital Markets | Reiterated | Buy | $42← $31 |
| April 30th 2024 | Morgan Stanley | Initiation | Overweight | $40 |
| February 20th 2024 | H.C. Wainwright | Initiation | Buy | $36 |
Earnings History & Surprises
DYNBeat Rate
39%
Last 18 quarters
Avg Surprise
-6.7%
EPS vs Estimate
Beats / Misses
7/10
1 met exactly
Latest EPS
$-0.76
Q4 2025
EPS Surprise History
Q1 24
-18.5%
$-1.09vs$-0.92
Q2 24
0.0%
$-0.81vs$-0.81
Q3 24
+2.8%
$-0.70vs$-0.72
Q4 24
-35.2%
$-0.96vs$-0.71
Q1 25
+4.3%
$-0.88vs$-0.92
Q2 25
-19.3%
$-1.05vs$-0.88
Q3 25
+2.0%
$-0.97vs$-0.99
Q4 25
+6.2%
$-0.76vs$-0.81
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.74 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.81 | $-0.76 | +6.2% | ✓ BEAT |
Q3 2025 | Jul 28, 2025 | $-0.99 | $-0.97 | +2.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.88 | $-1.05 | -19.3% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.92 | $-0.88 | +4.3% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.71 | $-0.96 | -35.2% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.72 | $-0.70 | +2.8% | ✓ BEAT |
Q2 2024 | May 2, 2024 | $-0.81 | $-0.81 | 0.0% | = MET |
Q1 2024 | Mar 5, 2024 | $-0.92 | $-1.09 | -18.5% | ✗ MISS |
Q4 2023 | Oct 30, 2023 | $-0.86 | $-0.99 | -15.1% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.81 | $-1.08 | -33.3% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.77 | $-0.78 | -1.3% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.84 | $-0.74 | +11.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.95 | $-0.80 | +15.8% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.79 | $-1.01 | -27.8% | ✗ MISS |
Q2 2022 | May 2, 2022 | $-0.88 | $-0.69 | +21.6% | ✓ BEAT |
Q1 2022 | Mar 10, 2022 | $-0.99 | $-1.00 | -1.0% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.65 | $-0.83 | -27.7% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.55 | $-0.58 | -5.5% | ✗ MISS |
Latest News
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screenings' - HHS
📈 PositiveBenzinga•Dec 16, 2025, 04:34 PM•Also: , ,
Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $36
➖ NeutralBenzinga•Dec 15, 2025, 02:54 PM
Stifel Maintains Buy on Dyne Therapeutics, Raises Price Target to $39
📈 PositiveBenzinga•Dec 11, 2025, 01:26 PM•Also:
Dyne Therapeutics shares are trading higher. The company announced the pricing of an upsized underwritten offering of 18,980,478 shares at $18.44.
➖ NeutralBenzinga•Dec 10, 2025, 04:03 PM
Oppenheimer Upgrades Dyne Therapeutics to Outperform, Raises Price Target to $40
📈 PositiveBenzinga•Dec 10, 2025, 03:11 PM
Reported Earlier, Dyne Therapeutics Prices Upsized Underwritten Offering Of 18,980,478 Common Shares At $18.44, Raising $350M For Neuromuscular Disease Programs
📈 PositiveBenzinga•Dec 10, 2025, 08:21 AM
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Dec 9, 2025, 05:20 PM
Dyne Therapeutics shares are trading lower after the company announced a $300 million public offering.
📉 NegativeBenzinga•Dec 9, 2025, 02:01 PM
Chardan Capital Maintains Buy on Dyne Therapeutics, Maintains $38 Price Target
📈 PositiveBenzinga•Dec 9, 2025, 01:23 PM
Dyne Therapeutics shares are trading lower after the company announced a $300 million public offering.
📉 NegativeBenzinga•Dec 8, 2025, 09:42 PM
Dyne Therapeutics Announces Proposed $300M Public Offering Of Common Stock
➖ NeutralBenzinga•Dec 8, 2025, 09:03 PM
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Raises Price Target to $60
📈 PositiveBenzinga•Dec 8, 2025, 02:49 PM
Dyne Therapeutics shares are trading higher after the company said its registrational expansion cohort in the Phase 1/2 DELIVER trial met the primary endpoint for its Duchenne muscular dystrophy therapy.
📈 PositiveBenzinga•Dec 8, 2025, 12:49 PM
Dyne Therapeutics' Registrational Expansion Cohort Of Phase 1/2 DELIVER Trial Of Zeleciment Rostudirsen For Duchenne Muscular Dystrophy Met Primary Endpoint
📈 PositiveBenzinga•Dec 8, 2025, 11:34 AM
Reported Sunday, Dyne Therapeutics To Announce Topline DELIVER Registrational Expansion Cohort Results For Z-Rostudirsen (DYNE-251) In DMD On Dec. 8, 2025
➖ NeutralBenzinga•Dec 8, 2025, 08:34 AM
JP Morgan Maintains Neutral on Dyne Therapeutics, Lowers Price Target to $17
➖ NeutralBenzinga•Nov 14, 2025, 03:52 PM
Oppenheimer Maintains Perform on Dyne Therapeutics, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 12, 2025, 04:16 PM
HC Wainwright & Co. Maintains Buy on Dyne Therapeutics, Raises Price Target to $46
📈 PositiveBenzinga•Nov 6, 2025, 04:37 PM
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $30
📈 PositiveBenzinga•Nov 6, 2025, 03:51 PM
Dyne Therapeutics Q3 EPS $(0.76) Beats $(0.85) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 10:08 PM
Frequently Asked Questions about DYN
What is DYN's current stock price?
Dyne Therapeutics, Inc. (DYN) is currently trading at $19.85 per share. The stock has moved +7.01% today.
What is the analyst price target for DYN?
The average analyst price target for DYN is $34.42, based on 1 analyst.
What sector is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is DYN's market cap?
Dyne Therapeutics, Inc. has a market capitalization of $2.84 billion, making it a mid-cap company.
Does DYN pay dividends?
No, Dyne Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$29.31
Mkt Cap: $2.7B
APGE
Apogee Therapeutics, Inc.
$78.54
Mkt Cap: $4.3B
CELC
Celcuity Inc.
$101.16
Mkt Cap: $4.7B
CGON
CG Oncology, Inc. Common stock
$39.03
Mkt Cap: $2.9B
CNTA
Centessa Pharmaceuticals plc
$24.85
Mkt Cap: $3.3B
MIRM
Mirum Pharmaceuticals, Inc.
$77.74
Mkt Cap: $3.8B
RARE
Ultragenyx Pharmaceutical Inc.
$33.50
Mkt Cap: $3.2B
SLNO
Soleno Therapeutics, Inc.
$47.85
Mkt Cap: $2.6B
TLX
Telix Pharmaceuticals Limited
$7.80
Mkt Cap: $2.6B
XENE
Xenon Pharmaceuticals Inc.
$44.10
Mkt Cap: $3.4B
Explore stocks similar to DYN for comparison